Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI - Free Report) by 79.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 82,489 shares of the company's stock after acquiring an additional 36,566 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.13% of Treace Medical Concepts worth $692,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also modified their holdings of TMCI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Treace Medical Concepts by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,001 shares of the company's stock valued at $208,000 after buying an additional 1,216 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its stake in shares of Treace Medical Concepts by 2.6% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 83,285 shares of the company's stock valued at $620,000 after buying an additional 2,150 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Treace Medical Concepts by 1.1% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 244,800 shares of the company's stock valued at $2,054,000 after buying an additional 2,645 shares in the last quarter. Palumbo Wealth Management LLC lifted its stake in shares of Treace Medical Concepts by 15.4% during the 1st quarter. Palumbo Wealth Management LLC now owns 25,690 shares of the company's stock valued at $216,000 after buying an additional 3,431 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Treace Medical Concepts by 22.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,056 shares of the company's stock valued at $142,000 after buying an additional 3,452 shares in the last quarter. Hedge funds and other institutional investors own 84.08% of the company's stock.
Treace Medical Concepts Stock Performance
Shares of NASDAQ TMCI opened at $7.04 on Tuesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.52. The company has a market cap of $444.72 million, a P/E ratio of -8.91 and a beta of 0.68. The firm's fifty day moving average is $5.92 and its two-hundred day moving average is $7.14. Treace Medical Concepts, Inc. has a 52-week low of $4.54 and a 52-week high of $10.79.
Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. The company had revenue of $47.39 million for the quarter, compared to the consensus estimate of $47.08 million. Treace Medical Concepts had a negative net margin of 23.01% and a negative return on equity of 46.76%. As a group, analysts anticipate that Treace Medical Concepts, Inc. will post -0.92 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
TMCI has been the topic of a number of analyst reports. UBS Group restated a "neutral" rating and set a $6.50 target price (down previously from $8.60) on shares of Treace Medical Concepts in a research note on Friday, August 8th. Stifel Nicolaus reduced their price target on shares of Treace Medical Concepts from $9.00 to $6.00 and set a "hold" rating on the stock in a report on Friday, August 8th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $9.83.
Read Our Latest Report on Treace Medical Concepts
Treace Medical Concepts Profile
(
Free Report)
Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Treace Medical Concepts, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Treace Medical Concepts wasn't on the list.
While Treace Medical Concepts currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access